# Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

> **NCT03209401** · PHASE1 · TERMINATED · sponsor: **Georgetown University** · enrollment: 23 (actual)

## Conditions studied

- Solid Tumor, Adult
- Homologous Recombination Deficiency

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03209401
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-13
- **Primary completion:** 2023-10-16
- **Final completion:** 2023-10-16
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2024-02-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03209401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03209401, "Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03209401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*